NASDAQ Soins de santé Biotechnologie TYRA

Tyra Biosciences, Inc.

$ 28.32 -2.58 %

Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.

CEO: Todd Harris - https://www.tyra.bio

Summary 30-Y Financials Dividend Analyst Historique indicateurs Possession / Senat
Price objectif

$50.5 78.32 %

Recommandation

Buy

DCF

$ 1.18

Loading data...

TYRA vs S&P500

Loading data...

No data available.

Quick ratio

20.49

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-12.99

may indicate that the company is undervalued or has poor growth prospects.

EPS

-2.18

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-42.66 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-36.34 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

7.78

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.01

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-1.66

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
1 indicates worrying financial health
Altman score
39.95 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
4.41 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.01 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.